Communiqués Vyome Holdings, Inc.

Actions

HIND

US92943X1046

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
2,060 ^USD	+2,49 %		+5,10 %	-40,12 %

03/09	Vyome Holdings, Inc. : Chardan Research à l'achat	ZM
28/08	Vyome Holdings, Inc. nomme Jerry Leonard aux postes de responsable financier et responsable comptable, avec effet au 1er septembre 2026	CI

Communiqués

14/09	Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer	BU
25/08	Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet	BU
01/07	Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio	BU
28/05	Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet	BU
12/05	Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity	BU
22/04	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026	BU
06/04	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026	BU
26/03	Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase	BU
18/02	Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity	BU
11/02	Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months	BU
02/02	Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results	BU
27/01	Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study	BU
22/12	Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company	BU
08/12	Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval	BU
25/11	Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program	BU
18/11	Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing	BU
04/11	Vyome Holdings Announces Results of Annual Shareholder Meeting	BU
29/09/25	Vyome Holdings Acquires MIT AI Spinout Oculo Health	BU
17/09/25	Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity	BU
09/09/25	Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies	BU
04/09/25	Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity	BU
21/08/25	Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio	BU
19/08/25	Vyome Announces Strategic Review of Livechain (OTCID: LICH)	AQ
15/08/25	Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND	AQ
15/08/25	Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow	BU